Increased incidence of fungemia caused by Candida krusei.
AUTOR(ES)
Merz, W G
RESUMO
Candida krusei colonized 12.4% of 868 patients undergoing episodes of therapy-induced granulocytopenia over a 9-year period. The gastrointestinal tract was most frequently colonized, followed by the respiratory tract and urinary tract. Ten patients developed systemic infections with C. krusei; all 10 had two or more positive blood cultures. Nine of the 10 patients were colonized with C. krusei, and 6 were receiving systemic antifungal agents at the time of development of the infection. Seven patients died within 1 month of C. krusei sepsis; systemic candidiasis was seen in the autopsies of the four patients on whom autopsies were performed. Therefore, C. krusei should be recognized as an emerging pathogen in select patient populations.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=268975Documentos Relacionados
- Strain variation among and antifungal susceptibilities of isolates of Candida krusei.
- A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
- Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.
- Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.
- Transient Fungemia Caused by an Amphotericin B-Resistant Isolate of Candida haemulonii